培塞利珠单抗几乎不转运至母乳:CRADLE前瞻性上市后多中心药代动力学研究结果
CRADLE是首个由企业资助的研究,评估培塞利珠单抗(CZP)在哺乳期母亲母乳中的浓度并估算婴儿日均剂量(ADID)。研究纳入17名接受CZP治疗的哺乳期母亲,结果显示母乳中CZP浓度极低或检测不到,中位相对婴儿剂量(RID)为0.15%,PEG未检出,婴儿安全性特征与未暴露婴儿一致,支持哺乳期继续使用CZP。
要点
- 母乳中CZP浓度低于定量下限3倍以下,RID中位0.15%,远低于10%的临床担忧阈值。
- PEG在134/137份母乳样本中未检出,婴儿经母乳吸收CZP可能性低。
- 暴露婴儿安全性特征与同龄未暴露婴儿一致,支持哺乳期继续CZP治疗。
核心结论
- 培塞利珠单抗从血浆向母乳的转移极少或无,RID中位0.15%远低于10%的临床担忧阈值。
研究设计与样本
- CRADLE(NCT02154425)为前瞻性、上市后、多中心药代动力学研究,纳入接受CZP的哺乳期母亲。
- 给药≥3剂后,在一个给药周期内采集母乳样本:200mg每2周者采集14天,400mg每4周者采集28天。
- 共筛查19名接受CZP治疗的母亲,17名进入采样期:16名接受200mg每2周,1名接受400mg每4周。
主要发现
- 77/137(56%)份母乳样本未检测到可定量CZP;4/17名母亲所有样本均低于定量下限(LLOQ)。
- 估算ADID为0-0.0104 mg/kg/day,RID中位0.15%。
- PEG在134/137份样本中未检出(3份样本结果无法确定)。
- 暴露婴儿的安全性特征与同龄未暴露婴儿一致。
关键数值与推荐
- 可定量时CZP浓度<3×LLOQ(<治疗剂量下血浆浓度的1%),提示无/极少CZP从血浆转运至母乳。
- RID为母体剂量的0.15%;<10%被认为不太可能具有临床担忧。
- 未观察到PEG转运;因CZP口服生物利用度低且无Fc结构,婴儿经母乳吸收可能性低。
临床怎么用
- 研究结果令人安心,支持哺乳期继续培塞利珠单抗治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of maternal CZP. METHODS: CRADLE (NCT02154425) was a pharmacokinetic study of lactating mothers receiving CZP. After ≥3 CZP doses, breast milk samples were collected across one dosing period (14 days for 200 mg every 2 weeks [Q2W]; 28 days for 400 mg every 4 weeks [Q4W]). Optimal analytical methods were developed to determine CZP and polyethylene glycol (PEG) levels in breast milk. ADID and relative infant dose (RID) were estimated. Safety events in mothers and infants were assessed. RESULTS: 19 CZP-treated mothers were screened; 17 entered the sampling period: 16 on 200 mg Q2W, 1 on 400 mg Q4W. 77/137 (56%) breast milk samples had no measurable CZP. For 4/17 mothers, all samples were below the lower limit of quantification (LLOQ). Estimated ADID was 0-0.0104 mg/kg/day; median RID: 0.15%. PEG was undetectable in 134/137 samples (results could not be determined in three samples). Infants of CZP-exposed mothers had a safety profile consistent with that of unexposed similar-age infants. CONCLUSION: When quantifiable, CZP concentrations were <3× LLOQ (<1% plasma concentration observed with therapeutic dose), indicating no/minimal CZP transfer from plasma to breast milk. RID was 0.15% of maternal dose; <10% is considered unlikely to be of clinical concern. No PEG transfer was observed. CZP absorption by infants via breast milk is unlikely due to its low oral bioavailability and Fc--free molecular structure. These findings are reassuring and support continuation of CZP treatment during breast feeding. TRIAL REGISTRATION NUMBER: NCT02154425; Results.
引用
- Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017. PMID: 28814432. doi:10.1136/annrheumdis-2017-211384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。